Free Trial
→ Ominous New Day in America (Get Ready for it) (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.08
+0.5%		$1.06
$0.74
▼
$1.74
$33.83M0.26145,922 shs27,270 shs
Briacell Therap stock logo
BCTX
Briacell Therap
$3.93
-1.8%		$3.76
$2.60
▼
$14.68
$34.17M1.21321,774 shs21,819 shs
Immuron stock logo
IMRN
Immuron
$1.10
+0.9%		$1.21
$0.68
▼
$2.39
$8.88M1.09777,400 shs12,654 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$5.54
+0.4%		$6.11
$8.50
▼
$23.00
$34.64MN/A37,647 shs7,551 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-3.60%-4.46%+3.88%+10.31%-32.28%
Briacell Therap stock logo
BCTX
Briacell Therap
-0.50%-6.54%+12.04%+9.89%-68.33%
Immuron stock logo
IMRN
Immuron
+0.93%-6.03%-39.44%-13.49%-50.57%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
-4.33%-9.51%-19.42%-26.89%-59.11%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.08
+0.5%		$1.06
$0.74
▼
$1.74
$33.83M0.26145,922 shs27,270 shs
Briacell Therap stock logo
BCTX
Briacell Therap
$3.93
-1.8%		$3.76
$2.60
▼
$14.68
$34.17M1.21321,774 shs21,819 shs
Immuron stock logo
IMRN
Immuron
$1.10
+0.9%		$1.21
$0.68
▼
$2.39
$8.88M1.09777,400 shs12,654 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$5.54
+0.4%		$6.11
$8.50
▼
$23.00
$34.64MN/A37,647 shs7,551 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-3.60%-4.46%+3.88%+10.31%-32.28%
Briacell Therap stock logo
BCTX
Briacell Therap
-0.50%-6.54%+12.04%+9.89%-68.33%
Immuron stock logo
IMRN
Immuron
+0.93%-6.03%-39.44%-13.49%-50.57%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
-4.33%-9.51%-19.42%-26.89%-59.11%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3.00
Buy$5.00365.12% Upside
Briacell Therap stock logo
BCTX
Briacell Therap
1.00
SellN/AN/A
Immuron stock logo
IMRN
Immuron
1.00
SellN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest IMRN, BCTX, IZTC, and ATNM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Immuron stock logo
IMRN
Immuron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Briacell Therap stock logo
BCTX
Briacell Therap
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$35.09M0.96N/AN/A$1.31 per share0.82
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A$9.20 per shareN/A
Immuron stock logo
IMRN
Immuron
$5.47M1.62N/AN/A$0.94 per share1.17
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M$0.36N/AN/AN/AN/A-100.85%-47.89%N/A
Briacell Therap stock logo
BCTX
Briacell Therap
-$26.31M-$7.92N/AN/AN/AN/A-153.53%-129.26%N/A
Immuron stock logo
IMRN
Immuron
-$2.50MN/AN/AN/AN/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest IMRN, BCTX, IZTC, and ATNM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q4 2026
Immuron stock logo
IMRN
Immuron
N/A-$0.08N/A-$0.0750N/A$1.27 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
Immuron stock logo
IMRN
Immuron
N/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
7.07
7.07
Immuron stock logo
IMRN
Immuron
N/A
7.26
5.98
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
Briacell Therap stock logo
BCTX
Briacell Therap
15.42%
Immuron stock logo
IMRN
Immuron
0.12%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A

Insider Ownership

CompanyInsider Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.60%
Briacell Therap stock logo
BCTX
Briacell Therap
0.74%
Immuron stock logo
IMRN
Immuron
7.01%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2531.44 million29.32 millionOptionable
Briacell Therap stock logo
BCTX
Briacell Therap
48.70 million8.64 millionNo Data
Immuron stock logo
IMRN
Immuron
78.07 million7.51 millionNot Optionable
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A

Recent News About These Companies

Invizyne Technologies (NASDAQ:IZTC) Stock Price Down 4.4% - Here's What Happened
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31076789
Institutional investors own a significant stake of 42% in Invizyne Technologies, Inc. (NASDAQ:IZTC)
February 13, 2025  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/institutional-investors-own-significant-stake-122811776.html
What’s in a Name: Out with Invizyne, In with eXoZymes
February 12, 2025  |  genengnews.comG
Invizyne Technologies rebrands as eXoZymes with new ticker EXOZ
February 11, 2025  |  msn.comhttps://www.msn.com/en-us/technology/tech-companies/invizyne-technologies-rebrands-as-exozymes-with-new-ticker-exoz/ar-AA1yLfmv
Invizyne announces corporate name change to eXoZymes
February 11, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invizyne-announces-corporate-name-change-to-exozymes-1034336391
Why Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 12.35%
February 4, 2025  |  aaii.comA
Why Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 10.33%
January 30, 2025  |  aaii.comA
Invizyne technologies CEO Michael Heltzen buys $20,345 in stock
January 21, 2025  |  msn.comhttps://www.msn.com/en-us/technology/tech-companies/invizyne-technologies-ceo-michael-heltzen-buys-20-345-in-stock/ar-AA1xAdEg
Invizyne Technologies Inc trading resumes
January 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invizyne-technologies-inc-trading-resumes-1034183742
Invizyne Technologies Inc trading halted, volatility trading pause
January 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invizyne-technologies-inc-trading-halted-volatility-trading-pause-1034183743
Michael Heltzen Buys 1,984 Shares of Invizyne Technologies Inc. (NASDAQ:IZTC) Stock
November 20, 2024  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-iztc-insider-buying-and-selling-2024-11-20/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.08 +0.01 (+0.47%)
As of 12:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$3.93 -0.07 (-1.78%)
As of 12:55 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Immuron stock logo

Immuron NASDAQ:IMRN

$1.10 +0.01 (+0.92%)
As of 12:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$5.54 +0.02 (+0.36%)
As of 10/7/2026

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas